<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736474</url>
  </required_header>
  <id_info>
    <org_study_id>MZhao-005</org_study_id>
    <nct_id>NCT02736474</nct_id>
  </id_info>
  <brief_title>Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia</brief_title>
  <official_title>Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to observe the efficacy of Naltrexone and Bupropion
      combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, and placebo-controlled study. Subjects with evaluation
      and confirmation that inclusion and exclusion criteria are met, will be treated with
      naltrexone sustained release 15mg once per day and bupropion sustained release 150mg once per
      day in the first two weeks, and naltrexone 25mg once per day and bupropion 300mg once per day
      during the rest of the study.The purpose of this research is to observe the efficacy of
      Naltrexone and Bupropion on weight loss and smoking cessation compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in weight at 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>evaluate all participants' weight ，weight in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of participants who quit smoking</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluate all participants' smoking statues by Exhale carbon monoxide concentrations in part per million。</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Craving for nicotine assessed by Visual Analog Scales (VAS) at 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>evaluate all participants' craving for nicotine by Visual Analog Scales (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression status assessed by Self-rating depression scale（SDS）</measure>
    <time_frame>Baseline，2,4,12，and 24 weeks</time_frame>
    <description>evaluate all participants' depression status by Self-rating depression scale（SDS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status assessed by Self-Rating Anxiety Scale（SAS）</measure>
    <time_frame>Baseline，2,4,12，and 24 weeks</time_frame>
    <description>evaluate all participants' depression status by Self-Rating Anxiety Scale（SAS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms assessed by the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline，2,4,12，and 24 weeks</time_frame>
    <description>evaluate all participants' Clinical symptoms by the Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms assessed by clinical global impressions scale（CGI）</measure>
    <time_frame>Baseline，2,4,12，and 24 weeks</time_frame>
    <description>evaluate all participants' Clinical symptoms by clinical global impressions scale（CGI）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference at 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>evaluate all participants' waist circumference，waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose Levels</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin Levels</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycosylated hemoglobin</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides Levels</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting HDL Cholesterol Levels</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment-Insulin Resistance Levels</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting LDL Cholesterol</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leptin</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ghrelin</measure>
    <time_frame>Baseline,12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting state functional connectivity of the brain reward circuits on weight loss and smoking cessation</measure>
    <time_frame>Baseline,24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Obese</condition>
  <condition>Cigarette-smoking</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.</description>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Naltrexone</intervention_name>
    <description>Placebo Naltrexone created and masked by the pharmacy to be used as a control.</description>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Bupropion</intervention_name>
    <description>Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia;

          -  On stable atypical antipsychotic medication regimen for at least one month;

          -  BMI &gt; 28 kg/m2 using the BMI criterion for obesity in the Chinese population;

          -  Smoking at least 10 cigarettes daily for a minimum of 1 year;

          -  Desire to lose weight and quit smoking.

        Exclusion Criteria:

          -  Binge eating or other eating disorders;

          -  Current use of weight loss or antidiabetic medications;

          -  Current substance use (except nicotine or caffeine);

          -  Elevated hepatic transaminase levels (&gt;2.5x normal range);

          -  Clinically significant Thyroid Stimulating Hormone（TSH） and/or thyroxine4（T4）
             abnormalities;

          -  History of seizure disorder;

          -  History of unstable cardiac problems or other unstable medication conditions;

          -  Being pregnant or nursing (for women).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Du, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Physician</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>DU, Jiang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Bupropion hydrochloride, naltrexone hydrochoride drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

